- Home
- ALT vs EAD Comparison
ALT vs EAD Comparison
Compare ALT & EAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALT | EAD |
|---|---|---|
| Founded | 1997 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 415.3M | 407.1M |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | ALT | EAD |
|---|---|---|
| Price | $3.55 | $6.69 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $16.00 | N/A |
| AVG Volume (30 Days) | ★ 2.8M | 146.4K |
| Earning Date | 06-10-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.91% |
| EPS Growth | ★ 25.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $756,308.50 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 105.00 | N/A |
| 52 Week Low | $2.91 | $5.89 |
| 52 Week High | $7.73 | $7.18 |
Technical Indicators
Market Signals| Indicator | ALT | EAD |
|---|---|---|
| Relative Strength Index (RSI) | 30.87 | 25.75 |
| Support Level | $3.39 | N/A |
| Resistance Level | $4.25 | $6.92 |
| Average True Range (ATR) | 0.24 | 0.04 |
| MACD | -0.10 | -0.02 |
| Stochastic Oscillator | 13.55 | 13.04 |
Price Performance
Historical ComparisonAbout ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
About EAD Allspring Income Opportunities Fund
Allspring Income Opportunities Fund is a diversified closed-end management investment company. Its products and services are mutual funds, closed-end funds, managed accounts services, and variable trust funds. The fund's objective is a high level of current income and capital appreciation. Its portfolio of investments is Commercial services, healthcare services, Food, Pharmaceuticals, Energy, Oil & gas, Pipelines, Diversified financial services, and Others.